Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antibacterials - Destiny Pharma

Drug Profile

Research programme: antibacterials - Destiny Pharma

Alternative Names: DPD201; DPD202; DPD204; DPD206; DPD207; DPD241; MQ drug series - Destiny Pharma; XF drug series - Destiny Pharma; XF-42; XF-70

Latest Information Update: 24 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Destiny Pharma
  • Class Metalloporphyrins; Porphyrins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections; Methicillin-resistant Staphylococcus aureus infections
  • Research Cystic fibrosis; Diabetic foot ulcer

Most Recent Events

  • 10 Sep 2019 Destiny Pharma signs research collaboration agreement with University of Sheffield for development of compounds (inclusive of DPD 207) from Destiny's XF-platform for Bacterial infections
  • 12 Apr 2019 Preclinical development is ongoing in United Kingdom (Destiny Pharma pipeline, April 2019)
  • 09 Apr 2019 Destiny Pharma has patent protection for XF-biofilm in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top